Results 51 to 60 of about 19,810 (202)

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

, 2020
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic eff ects related to high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug with a 90% reduction in plasma tenofovir concentrations ...
Michael Saag, Anton Pozniak, Frank Post, Michael T Yin, Edwin Dejesus, Benoit Trottier, Hal Martin, Shinichi Oka, Andrew K Cheng, Jaime Andrade-Villanueva, Lijie Zhong, Melanie Thompson, Joseph M Custodio, Jean Michel Molina, David Wohl, Paul E Sax, Ellen Koenig, Huyen Cao, Christian Callebaut, Gordon Crofoot, Daniel Podzamczer, Andrew Plummer, Marshall W Fordyce, Scott   +23 more
core  

Clinical Outcomes of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People Living With HIV and Low-Level Viraemia

Journal of the International Association of Providers of AIDS Care
Introduction Low-level viraemia (LLV) in people living with HIV (PLWH) remains a clinical challenge, associated with increased risk of virological failure, immune dysregulation, and chronic inflammation. Bictegravir/emtricitabine/tenofovir alafenamide is
Ignacio de los Santos, Guillermo Pousada, Carlos Galera, Carlos Dueñas, Luis Buzón, José Sanz, Cristina Martín, María Ángeles Garcinuño, María José Galindo, Lucio García-Fraile, Roberto Pedrero-Tomé, Jesús Troya   +11 more
doaj   +1 more source

The Emerging Role of China in the Innovation, Individualization, and Translation of Antiviral Therapeutics for Chronic Hepatitis B

Portal Hypertension &Cirrhosis, EarlyView.
This perspective outlines China's contributions toward functional‐cure‐oriented antiviral therapies for chronic hepatitis B, summarizing key clinical data on bepirovirsen and domestic drug pipelines with balanced coverage of both promising and disappointing trial results.
Dandan Weng, Zhujun Cao, Qing Xie
wiley   +1 more source

HIV‐associated nephropathy: A decade of clinical outcomes, global disparities and emerging promise

HIV Medicine, EarlyView.
Abstract Objective To review the pathogenesis, epidemiology, clinical presentation, management and outcomes of HIV‐associated nephropathy (HIVAN), with emphasis on global disparities, genetic susceptibility (APOL1) and emerging therapeutic and technological advances.
Deepak V. Pathiyil, Nicola Wearne, Brendon Price, Frank Post, Dami A. Collier   +4 more
wiley   +1 more source

Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir

, 2022
In the present study, the mean increases reported in weight, BMI, and waist circumference after 12 months were comparable in naive patients starting abacavir/ lamivudine/dolutegraviror tenofovir alafenamide/emtricitabine ...
Calza L, Miani T, Lazzarotto T, Colangeli V, Viale P, Borderi M, Bon I, Nuti B   +7 more
core   +1 more source

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide

Frontiers in Pharmacology, 2020
Background: HIV pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine is effective when taken daily. Previously, we developed a urine assay capable of detecting the prodrug tenofovir (TFV) in patients taking tenofovir disoproxil fumarate (TDF ...
Linden Lalley-Chareczko, Emily Hiserodt, Ganesh Moorthy, Athena Zuppa, Karam Mounzer, Helen Koenig, Helen Koenig   +6 more
doaj   +1 more source

Discordant Liver Fibrosis Predictors in Virologically Suppressed People Living with HIV without Hepatitis Virus Infection

Diagnostics, 2021
Severe liver fibrosis (LF) is associated with poor long-term liver-related outcomes in people living with HIV (PLWH). The study aimed to explore the prevalence and predictors of LF and the concordance between different non-invasive methods for the ...
Barbara Rossetti, Valentina Borgo, Arianna Emiliozzi, Marta Colaneri, Giacomo Zanelli, Miriana d’Alessandro, Davide Motta, Laura Maiocchi, Francesca Montagnani, Maria Cristina Moioli, Chiara Baiguera, Margherita Sambo, Teresa Chiara Pieri, Pietro Valsecchi, Raffaele Bruno, Massimo Puoti, Massimiliano Fabbiani   +16 more
doaj   +1 more source

A cross‐sectional analysis of cardiometabolic and lifestyle‐related profiles in men living with HIV in Japan using linked nationwide claims and health checkup data

HIV Medicine, EarlyView.
Abstract Objectives To compare objectively measured cardiometabolic health between people living with HIV (PLWH) and individuals without HIV using nationwide health checkup data linked to administrative claims, thereby partially mitigating surveillance bias associated with routine HIV care.
Kohei Yamashita, Kazuhiko Ikeuchi, Ryoko Sekiya, Yuki Arisato, Shinya Matsumoto, Toshiyuki Kishida, Akira Kado, Kazuya Okushin, Hiroshi Yotsuyanagi, Takeya Tsutsumi   +9 more
wiley   +1 more source

A systematic review of evidence on weight change following initiation of long‐acting cabotegravir for the prevention or treatment of HIV

HIV Medicine, EarlyView.
Abstract Background Weight gain is an increasingly recognized concern among people receiving antiretroviral therapy (ART) and may increase the risk of non‐communicable diseases. Integrase inhibitors (INSTIs) such as dolutegravir (DTG) have been associated with weight gain, but the metabolic effects of long‐acting cabotegravir (CAB‐LA), another INSTI ...
Jonathan Kitonsa, Ronald Komata, Wilber Ssembajjwe, Daniel Grint, Julian Robinson, Eugene Ruzagira, Robert Kalyesubula, Jaime Vera, Fiona Cresswell   +8 more
wiley   +1 more source

Articles Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

, 2020
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic eff ects related to high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug with a 90% reduction in plasma tenofovir concentrations ...
Michael Saag, Anton Pozniak, Frank Post, Michael T Yin, Edwin Dejesus, Benoit Trottier, Hal Martin, Shinichi Oka, Andrew K Cheng, Jaime Andrade-Villanueva, Lijie Zhong, Melanie Thompson, Joseph M Custodio, Jean Michel Molina, David Wohl, Paul E Sax, Ellen Koenig, Huyen Cao, Christian Callebaut, Gordon Crofoot, Daniel Podzamczer, Andrew Plummer, Marshall W Fordyce, Scott   +23 more
core